Gianfranco Amicosante

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5656473/publications.pdf

Version: 2024-02-01

126 papers	6,194 citations	66343 42 h-index	74163 75 g-index
126 all docs	126 docs citations	126 times ranked	4725 citing authors

#	Article	IF	Citations
1	Cloning and Characterization of bla _{VIM} , a New Integron-Borne Metallo-Î²-Lactamase Gene from a Pseudomonas aeruginosa Clinical Isolate. Antimicrobial Agents and Chemotherapy, 1999, 43, 1584-1590.	3.2	581
2	Characterization of the Metallo-Î²-Lactamase Determinant of Acinetobacter baumannii AC-54/97 Reveals the Existence of bla _{IMP} Allelic Variants Carried by Gene Cassettes of Different Phylogeny. Antimicrobial Agents and Chemotherapy, 2000, 44, 1229-1235.	3.2	245
3	Biochemical Characterization of the Pseudomonas aeruginosa 101/1477 Metallo-Î²-Lactamase IMP-1 Produced by Escherichia coli. Antimicrobial Agents and Chemotherapy, 1999, 43, 902-906.	3.2	212
4	Multiple CTX-M-Type Extended-Spectrum Î²-Lactamases in Nosocomial Isolates of Enterobacteriaceae from a Hospital in Northern Italy. Journal of Clinical Microbiology, 2003, 41, 4264-4269.	3.9	201
5	Zn(II) Dependence of theAeromonas hydrophilaAE036 Metallo-Î²-lactamase Activity and Stabilityâ€. Biochemistry, 1997, 36, 11534-11541.	2.5	184
6	Structure of In31, a bla _{IMP} -Containing Pseudomonas aeruginosa Integron Phyletically Related to In5, Which Carries an Unusual Array of Gene Cassettes. Antimicrobial Agents and Chemotherapy, 1999, 43, 890-901.	3.2	152
7	On functional and structural heterogeneity of VIM-type metallo-beta-lactamases. Journal of Antimicrobial Chemotherapy, 2003, 51, 257-266.	3.0	146
8	Metallo-Î²-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. International Journal of Antimicrobial Agents, 2007, 29, 380-388.	2.5	134
9	Proteus mirabilis Bloodstream Infections: Risk Factors and Treatment Outcome Related to the Expression of Extended-Spectrum Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2005, 49, 2598-2605.	3.2	130
10	The 1.5-Ã... Structure of Chryseobacterium meningosepticum Zinc Î²-Lactamase in Complex with the Inhibitor, D-Captopril. Journal of Biological Chemistry, 2003, 278, 23868-23873.	3.4	126
11	IMP-12, a New Plasmid-Encoded Metallo-Î²-Lactamase from a Pseudomonas putida Clinical Isolate. Antimicrobial Agents and Chemotherapy, 2003, 47, 1522-1528.	3.2	125
12	Spread of blaCTX-M-type and blaPER-2 Î²-lactamase genes in clinical isolates from Bolivian hospitals. Journal of Antimicrobial Chemotherapy, 2006, 57, 975-978.	3.0	118
13	Molecular Characterization of Extended-Spectrum Â-Lactamases Produced by Nosocomial Isolates of Enterobacteriaceae from an Italian Nationwide Survey. Journal of Clinical Microbiology, 2002, 40, 611-614.	3.9	116
14	Cytotoxic Activity and Antioxidant Capacity of Purified Lichen Metabolites: An In Vitro Study. Phytotherapy Research, 2013, 27, 431-437.	5.8	116
15	Substrate-activated Zinc Binding of Metallo-Î²-lactamases. Journal of Biological Chemistry, 2002, 277, 24142-24147.	3.4	115
16	Characterization and sequence of the Chryseobacterium (Flavobacterium) meningosepticum carbapenemase: a new molecular class B Î²-lactamase showing a broad substrate profile. Biochemical Journal, 1998, 332, 145-152.	3.7	113
17	Trends in Production of Extended-Spectrum Î²-Lactamases among Enterobacteria of Medical Interest: Report of the Second Italian Nationwide Survey. Journal of Clinical Microbiology, 2006, 44, 1659-1664.	3.9	110
18	CTX-M-Type Extended-Spectrum Î²-Lactamases in Italy: Molecular Epidemiology of an Emerging Countrywide Problem. Antimicrobial Agents and Chemotherapy, 2006, 50, 2700-2706.	3.2	107

#	Article	IF	Citations
19	Thiomandelic Acid, a Broad Spectrum Inhibitor of Zinc Î²-Lactamases. Journal of Biological Chemistry, 2001, 276, 45015-45023.	3.4	105
20	Nosocomial Infections Caused by Multidrug-Resistant Isolates of Pseudomonas putida Producing VIM-1 Metallo-Î²-Lactamase. Journal of Clinical Microbiology, 2002, 40, 4051-4055.	3.9	105
21	Bacteremia Due toKlebsiella pneumoniaeIsolates Producing the TEMâ€52 Extendedâ€Spectrum Î²â€Lactamase: Treatment Outcome of Patients Receiving Imipenem or Ciprofloxacin. Clinical Infectious Diseases, 2004, 38, 243-251.	5.8	105
22	Emergence in Klebsiella pneumoniae and Enterobacter cloacae Clinical Isolates of the VIM-4 Metallo-Î²-Lactamase Encoded by a Conjugative Plasmid. Antimicrobial Agents and Chemotherapy, 2004, 48, 648-650.	3.2	103
23	Parp1 Localizes within the Dnmt1 Promoter and Protects Its Unmethylated State by Its Enzymatic Activity. PLoS ONE, 2009, 4, e4717.	2.5	97
24	Evolution of CTX-M-type Î²-lactamases in isolates of Escherichia coli infecting hospital and community patients. International Journal of Antimicrobial Agents, 2005, 25, 157-162.	2.5	94
25	Emerging Extended-Spectrum Î²-Lactamases in Proteus mirabilis. Journal of Clinical Microbiology, 2002, 40, 1549-1552.	3.9	88
26	Purification and Biochemical Characterization of the VIM-1 Metallo-Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2000, 44, 3003-3007.	3.2	83
27	Metallo-Î²-Lactamase Producers in Environmental Microbiota: New Molecular Class B Enzyme in Janthinobacterium lividum. Antimicrobial Agents and Chemotherapy, 2001, 45, 837-844.	3.2	83
28	Simple Microdilution Test for Detection of Metallo-Î²-Lactamase Production in Pseudomonas aeruginosa. Journal of Clinical Microbiology, 2002, 40, 4388-4390.	3.9	77
29	Cerium oxide nanoparticles as potential antibiotic adjuvant. Effects of CeO2 nanoparticles on bacterial outer membrane permeability. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 2428-2435.	2.6	76
30	Dynamics of a Nosocomial Outbreak of Multidrug-Resistant Pseudomonas aeruginosa Producing the PER-1 Extended-Spectrum Î²-Lactamase. Journal of Clinical Microbiology, 2001, 39, 1865-1870.	3.9	74
31	In vitro interaction of usnic acid in combination with antimicrobial agents against methicillin-resistant Staphylococcus aureus clinical isolates determined by FICI and Î”E model methods. Phytomedicine, 2012, 19, 341-347.	5.3	73
32	Biochemical Characterization of the FEZ-1 Metallo-Î²-Lactamase of Legionella gormanii ATCC 33297 T Produced in Escherichia coli. Antimicrobial Agents and Chemotherapy, 2001, 45, 1254-1262.	3.2	66
33	TheAeromonasMetallo-Î²-Lactamases: Genetics, Enzymology, and Contribution to Drug Resistance. Microbial Drug Resistance, 1996, 2, 245-252.	2.0	63
34	The Legionella (Fluoribacter) gormanii Metallo-Î²-Lactamase: a New Member of the Highly Divergent Lineage of Molecular-Subclass B3 Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2000, 44, 1538-1543.	3.2	63
35	CAU-1, a Subclass B3 Metallo-Î²-Lactamase of Low Substrate Affinity Encoded by an Ortholog Present in the Caulobacter crescentus Chromosome. Antimicrobial Agents and Chemotherapy, 2002, 46, 1823-1830.	3.2	58
36	First Countrywide Survey of Acquired Metallo-Î²-Lactamases in Gram-Negative Pathogens in Italy. Antimicrobial Agents and Chemotherapy, 2008, 52, 4023-4029.	3.2	58

#	Article	IF	Citations
37	Identification of blaIMP-22 in Pseudomonas spp. in urban wastewater and nosocomial environments: biochemical characterization of a new IMP metallo-enzyme variant and its genetic location. Journal of Antimicrobial Chemotherapy, 2009, 63, 901-908.	3.0	55
38	Infections with VIM-1 Metallo-Î²-Lactamase-Producing Enterobacter cloacae and Their Correlation with Clinical Outcome. Journal of Clinical Microbiology, 2009, 47, 3514-3519.	3.9	54
39	Kinetic and spectroscopic characterization of native and metal-substituted Î²-lactamase from Aeromonas hydrophila AE036. FEBS Letters, 2000, 467, 221-225.	2.8	48
40	Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of Î²-lactam/Î²-lactamase inhibitor combinations. International Journal of Antimicrobial Agents, 2001, 17, 131-135.	2.5	46
41	Cloning of a Chryseobacterium (Flavobacterium) meningosepticum Chromosomal Gene (blaA _{CME}) Encoding an Extended-Spectrum Class A Î²-Lactamase Related to the Bacteroides Cephalosporinases and the VEB-1 and PER Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 1999, 43, 2193-2199.	3.2	46
42	PER-1 Extended-Spectrum Î²-Lactamase Production in anAlcaligenes faecalisClinical Isolate Resistant to Expanded-Spectrum Cephalosporins and Monobactams from a Hospital in Northern Italy. Microbial Drug Resistance, 2000, 6, 85-90.	2.0	45
43	Hydroxamate Inhibitors ofAeromonas hydrophilaAE036 Metallo-B-lactamase. Bioorganic Chemistry, 1999, 27, 35-40.	4.1	42
44	Optimizing Cell Permeation of an Antibiotic Resistance Inhibitor for Improved Efficacy. Journal of Medicinal Chemistry, 2007, 50, 5644-5654.	6.4	41
45	Multidrug-ResistantPseudomonas aeruginosaProducing PER-1 Extended-Spectrum Serine-Î²-Lactamase and VIM-2 Metallo-Î²-Lactamase. Emerging Infectious Diseases, 2001, 7, 910-911.	4.3	40
46	Novel 3- N -Aminoglycoside Acetyltransferase Gene, aac (3)- Ic , from a Pseudomonas aeruginosa Integron. Antimicrobial Agents and Chemotherapy, 2003, 47, 1746-1748.	3.2	40
47	Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase. BMC Infectious Diseases, 2006, 6, 52.	2.9	40
48	Curcumin inhibits the SOS response induced by levofloxacin in Escherichia coli. Phytomedicine, 2014, 21, 430-434.	5.3	37
49	TEM-72, a New Extended-Spectrum Î²-Lactamase Detected in Proteus mirabilis and Morganella morganii in Italy. Antimicrobial Agents and Chemotherapy, 2000, 44, 2537-2539.	3.2	35
50	SOS response in bacteria: Inhibitory activity of lichen secondary metabolites against Escherichia coli RecA protein. Phytomedicine, 2017, 29, 11-18.	5.3	34
51	Characterization of OXA-29 from Legionella (Fluoribacter) gormanii : Molecular Class D Î²-Lactamase with Unusual Properties. Antimicrobial Agents and Chemotherapy, 2001, 45, 3509-3516.	3.2	33
52	Chromosomal bla CTX-M-15 associated with ISEcp1 in Proteus mirabilis and Morganella morganii isolated at the Military Hospital of Tunis, Tunisia. Journal of Medical Microbiology, 2012, 61, 1286-1289.	1.8	33
53	In vitro antimicrobial activity of pannarin alone and in combination with antibiotics against methicillin-resistant Staphylococcus aureus clinical isolates. Phytomedicine, 2012, 19, 596-602.	5.3	33
54	Interaction between lichen secondary metabolites and antibiotics against clinical isolates methicillin-resistant Staphylococcus aureus strains. Phytomedicine, 2015, 22, 223-230.	5.3	33

#	Article	IF	Citations
55	Prevalence and characterization of metallo-Î²-lactamases in clinical isolates of pseudomonas aeruginosaâ˜†. Diagnostic Microbiology and Infectious Disease, 2004, 48, 131-135.	1.8	31
56	Overproduction and Biochemical Characterization of the Chryseobacterium meningosepticum BlaB Metallo-Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2002, 46, 1921-1927.	3.2	30
57	Cloning and nucleotide sequencing of the gene encoding the ÃŽÂ²-lactamase fromCitrobacter diversus. FEMS Microbiology Letters, 1991, 83, 79-84.	1.8	27
58	Dynamical Aspects of TEM-1 Î²-Lactamase Probed by Molecular Dynamics. Journal of Computer-Aided Molecular Design, 2005, 19, 329-340.	2.9	27
59	PHOTOHEMOLYSIS OF ERYTHROCYTES ENRICHED WITH SUPEROXIDE DISMUTASE, CATALASE AND GLUTATHIONE PEROXIDASE. Photochemistry and Photobiology, 1986, 43, 409-412.	2.5	26
60	Inactivation ofAeromonas hydrophilametallo-Î²-lactamase by cephamycins and moxalactam. FEBS Journal, 2001, 268, 3840-3850.	0.2	26
61	Ceftazidime and Aztreonam Resistance in Providencia stuartii : Characterization of a Natural TEM-Derived ExtendedSpectrum Î²-Lactamase, TEM-60. Antimicrobial Agents and Chemotherapy, 1998, 42, 1459-1462.	3.2	25
62	Natural D240G Toho-1 mutant conferring resistance to ceftazidime: biochemical characterization of CTX-M-43. Journal of Antimicrobial Chemotherapy, 2008, 62, 991-997.	3.0	25
63	Overproduction and Purification of the Aeromonas hydrophila CphA Metallo-Î²-Lactamase Expressed in Escherichia coli. Microbial Drug Resistance, 1996, 2, 253-256.	2.0	23
64	Enhanced active efflux, repression of porin synthesis and development of Mar phenotype by diazepam in two enterobacteria strains. Journal of Medical Microbiology, 2004, 53, 1119-1122.	1.8	23
65	Occurrence of Class 1 and 2 Integrons in Resistant Enterobacteriaceae Collected from a Urban Wastewater Treatment Plant: First Report from Central Italy. Microbial Drug Resistance, 2011, 17, 229-234.	2.0	23
66	Identification of CTX-M-15 and CTX-M-27 in Antibiotic-Resistant Gram-Negative Bacteria Isolated from Three Rivers Running in Central Italy. Microbial Drug Resistance, 2019, 25, 1041-1049.	2.0	23
67	Carbapenem-resistant Klebsiella pneumoniae harbouring blaKPC-3 and blaVIM-2 from central Italy. Diagnostic Microbiology and Infectious Disease, 2013, 75, 218-221.	1.8	22
68	Contribution of Î²-lactamase production to the resistance of mycobacteria to Î²-lactam antibiotics. FEBS Letters, 1997, 406, 275-278.	2.8	21
69	Can Non-steroidal Anti-inflammatory Drugs Act as Metalloproteinase Modulators? An In-vitro Study-of Inhibition of Collagenase Activity. Journal of Pharmacy and Pharmacology, 2011, 50, 1417-1423.	2.4	21
70	Antibacterial activity of selected metabolites from Chilean lichen species against methicillin-resistant staphylococci. Natural Product Research, 2013, 27, 1528-1531.	1.8	20
71	Emergence of blaKPC-3â€“Tn4401a in Klebsiella pneumoniae ST512 in the municipal wastewater treatment plant and in the university hospital of a town in central Italy. Journal of Global Antimicrobial Resistance, 2013, 1, 217-220.	2.2	20
72	Citrobacter diversus ULA27 produces two forms of a chromosomal Î²-lactamase. Journal of Antimicrobial Chemotherapy, 1987, 20, 23-35.	3.0	18

#	Article	IF	Citations
73	Dissemination of CTX-M-Type Extended-Spectrum Î²-Lactamase Genes to Unusual Hosts. Journal of Clinical Microbiology, 2005, 43, 4183-4185.	3.9	18
74	Class I Integron-Bornebla_{VIM-1}Carbapenemase in a Strain ofEnterobacter cloacaeResponsible for a Case of Fatal Pneumonia. Microbial Drug Resistance, 2008, 14, 45-47.	2.0	18
75	Comment on: Redefining extended-spectrum Â-lactamases: balancing science and clinical need. Journal of Antimicrobial Chemotherapy, 2009, 64, 212-213.	3.0	18
76	Protolichesterinic acid enhances doxorubicin-induced apoptosis in HeLa cells in vitro. Life Sciences, 2016, 158, 89-97.	4.3	18
77	Electrophoretic detection of ascorbate oxidase activity by photoreduction of nitroblue tetrazolium. Analytical Biochemistry, 1990, 188, 101-104.	2.4	17
78	Identification and Characterization of a New Metallo-Î²-Lactamase, IND-5, from a Clinical Isolate of Chryseobacterium indologenes. Antimicrobial Agents and Chemotherapy, 2007, 51, 2988-2990.	3.2	17
79	BlaB-15, a new BlaB metallo-Î²-lactamase variant found in an Elizabethkingia miricola clinical isolate. Diagnostic Microbiology and Infectious Disease, 2016, 85, 195-197.	1.8	17
80	Italian Survey on Comparative Levofloxacin Susceptibility in 334 Clinical Isolates of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 1999, 43, 428-431.	3.2	17
81	Prevalence of extended spectrum Î²-lactamases among Enterobacteriaceae: an Italian survey. International Journal of Antimicrobial Agents, 2002, 19, 213-217.	2.5	16
82	Evidence for qnrB1 and aac(6â€²)-Ib-cr in CTX-M-15â€“producing uropathogenic Enterobacteriaceae in an Italian teaching hospital. Diagnostic Microbiology and Infectious Disease, 2009, 64, 90-93.	1.8	16
83	Inhibition of the transcriptional repressor LexA: Withstanding drug resistance by inhibiting the bacterial mechanisms of adaptation to antimicrobials. Life Sciences, 2020, 241, 117116.	4.3	16
84	Whole-Genome Sequencing (WGS) of Carbapenem-Resistant K. pneumoniae Isolated in Long-Term Care Facilities in the Northern Italian Region. Microorganisms, 2021, 9, 1985.	3.6	16
85	Bactericidal activity of levofloxacin and ciprofloxacin on clinical isolates of different phenotypes of Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 2000, 13, 223-226.	2.5	15
86	Characterization of a New Extended-Spectrum Î²-Lactamase (TEM-87) Isolated in Proteus mirabilis during an Italian Survey. Antimicrobial Agents and Chemotherapy, 2002, 46, 925-928.	3.2	15
87	Novel TEM-Type Extended-Spectrum Î²-Lactamase, TEM-134, in a Citrobacter koseri Clinical Isolate. Antimicrobial Agents and Chemotherapy, 2005, 49, 1564-1566.	3.2	15
88	Fractionation and characterization of two Î²-lactamases in Citrobacter diversus ULA-27 strain by chromatofocusing. Journal of Chromatography A, 1987, 403, 366-372.	3.7	14
89	Comparative Activity of Piperacillin/Tazobactam against Clinical Isolates of Extended- Spectrum Î²-Lactamase-Producing Enterobacteriaceae. Chemotherapy, 1998, 44, 377-384.	1.6	14
90	Occurrence of Extended SpectrumÎ²-Lactamases Among Isolates of Enterobacteriaceae from Urinary Tract Infections in Southern Italy. Microbial Drug Resistance, 2006, 12, 257-264.	2.0	14

#	Article	IF	Citations
91	E240V Substitution Increases Catalytic Efficiency toward Ceftazidime in a New Natural TEM-Type Extended-Spectrum Î²-Lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2008, 52, 915-919.	3.2	14
92	Prevalence of quinolone resistance determinantqnrA6 among broad- and extended-spectrum beta-lactam-resistant Proteus mirabilis and Morganella morganii clinical isolates withsul1-type class 1 integron association in a Tunisian Hospital. Scandinavian Journal of Infectious Diseases, 2013, 45, 600-605.	1.5	14
93	OXA-23 Carbapenemase in Multidrug-ResistantAcinetobacter baumanniiST2 Type: First Identification in L'Aquila Hospital (Italy). Microbial Drug Resistance, 2015, 21, 97-101.	2.0	14
94	Influence of Sulfobetaines on the Stability of the Citrobacter diversus ULA-27 Î²-lactamase. Biotechnology Progress, 2001, 17, 1008-1013.	2.6	13
95	Spread of Enterobacteriaceae carrying the PER-1 extended-spectrum Â-lactamase gene as a chromosomal insert: a report from Italy. Journal of Antimicrobial Chemotherapy, 2006, 59, 323-324.	3.0	13
96	Persistence of TEM-52/TEM-92 and SHV-12 Extended-Spectrum Î²-Lactamases in Clinical Isolates of Enterobacteriaceae in Italy. Microbial Drug Resistance, 2011, 17, 521-524.	2.0	12
97	Identification of New Natural CphA Metallo-Î²-Lactamases CphA4 and CphA5 in Aeromonas veronii and Aeromonas hydrophila Isolates from Municipal Sewage in Central Italy. Antimicrobial Agents and Chemotherapy, 2015, 59, 4990-4993.	3.2	12
98	Kinetic Studies on CphA Mutants Reveal the Role of the P158-P172 Loop in Activity versus Carbapenems. Antimicrobial Agents and Chemotherapy, 2016, 60, 3123-3126.	3.2	11
99	Kinetic Profile and Molecular Dynamic Studies Show that Y229W Substitution in an NDM-1/L209F Variant Restores the Hydrolytic Activity of the Enzyme toward Penicillins, Cephalosporins, and Carbapenems. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	11
100	Antimicrobial susceptibility of clinical isolates of Enterobacteriaceae producing complex Î²-lactamase patterns including extended-spectrum enzymes. International Journal of Antimicrobial Agents, 2004, 23, 480-486.	2.5	10
101	Rifamycins as inhibitors of collagenase activity: Their possible pharmacological role in collagen degradative diseases. International Journal of Pharmaceutics, 1996, 144, 27-35.	5.2	9
102	Molecular characterization of carbapenem-resistant Klebsiella pneumoniae ST14 and ST512 causing bloodstream infections in ICU and surgery wards of a tertiary university hospital of Verona (northern Italy): co-production of KPC-3, OXA-48, and CTX-M-15 Î²-lactamases. Diagnostic Microbiology and Infectious Disease, 2020, 96, 114968.	1.8	9
103	First identification of an SHV-12 extended-spectrum Î²-lactamase in Klebsiella pneumoniae isolated in Italy. Journal of Antimicrobial Chemotherapy, 2000, 45, 349-351.	3.0	8
104	Biochemical Characterization of Laboratory Mutants of Extended-Spectrum Î²-Lactamase TEM-60. Antimicrobial Agents and Chemotherapy, 2004, 48, 3579-3582.	3.2	8
105	Biochemical analysis of TEM-134, a new TEM-type extended-spectrum Â-lactamase variant produced in a Citrobacter koseri clinical isolate from an Italian hospital. Journal of Antimicrobial Chemotherapy, 2007, 60, 877-880.	3.0	8
106	Cyclic and Acyclic Amine Oxide Alkyl Derivatives as Potential Adjuvants in Antimicrobial Chemotherapy against Methicillin-Resistant Staphylococcus aureus with an MDR Profile. Antibiotics, 2021, 10, 952.	3.7	8
107	The ultraviolet derivative spectrophotometric determination of neutral liposome-entrapped Î²-lactam antibiotics. Journal of Pharmaceutical and Biomedical Analysis, 1989, 7, 1159-1164.	2.8	7
108	Ceftibuten stability to active-site serine and metallo-ÃŸ-lactamases. International Journal of Antimicrobial Agents, 2001, 17, 45-50.	2.5	6

#	Article	IF	Citations
109	Biochemical Characterization of TEM-92 Extended-Spectrum Î²-Lactamase, a Protein Differing from TEM-52 in the Signal Peptide. Antimicrobial Agents and Chemotherapy, 2002, 46, 3981-3983.	3.2	6
110	Salicylate decreases production of AmpC type ÃŽÂ²-lactamases and increases susceptibility to ÃŽÂ²-lactams in aMorganella morganiiclinical isolate. FEMS Microbiology Letters, 2004, 238, 139-144.	1.8	6
111	Inhibitory Potential of Polyclonal Camel Antibodies against New Delhi Metallo-Î²-lactamase-1 (NDM-1). Molecules, 2020, 25, 4453.	3.8	5
112	Salicylate decreases production of AmpC type ?-lactamases and increases susceptibility to ?-lactams in a clinical isolate. FEMS Microbiology Letters, 2004, 238, 139-144.	1.8	4
113	TEM-184, a Novel TEM-Derived Extended-Spectrum Î²-Lactamase with Enhanced Activity against Aztreonam. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	4
114	First Identification of Î²-Lactamases in Antibiotic-Resistant Escherichia coli, Citrobacter freundii, and Aeromonas spp. Isolated in Stream Macroinvertebrates in a Central Italian Region. Microbial Drug Resistance, 2020, 26, 976-981.	2.0	4
115	On the structural affinity of macromolecules with different biological properties: Molecular dynamics simulations of a series of TEM-1 mutants. Biochemical and Biophysical Research Communications, 2013, 436, 666-671.	2.1	3
116	Kinetic Study of the Effect of Histidines 240 and 164 on TEM-149 Enzyme Probed by Î²-Lactam Inhibitors. Antimicrobial Agents and Chemotherapy, 2014, 58, 6294-6296.	3.2	3
117	Overexpression system and biochemical profile of CTX-M-3 extended-spectrum ÃŽÂ²-lactamase expressed inEscherichia coli. FEMS Microbiology Letters, 2004, 241, 229-232.	1.8	2
118	Ciprofloxacin, Salicylate, and 2,4-Dinitrophenol Decrease Production of AmpC-Type Î²-Lactamase in TwoCitrobacter freundiiClinical Isolates. Microbial Drug Resistance, 2005, 11, 225-231.	2.0	2
119	Protocetraric and Salazinic Acids as Potential Inhibitors of SARS-CoV-2 3CL Protease: Biochemical, Cytotoxic, and Computational Characterization of Depsidones as Slow-Binding Inactivators. Pharmaceuticals, 2022, 15, 714.	3.8	2
120	A Two Amino Acid Duplication, L167E168, in the Î©-Loop Drastically Decreases Carbapenemase Activity of KPC-53, a Natural Class A Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	2
121	Corrigendum to: Kinetic and spectroscopic characterization of native and metal-substituted Î²-lactamase from Aeromonas hydrophila AE036 (FEBS 23250). FEBS Letters, 2000, 477, 285-285.	2.8	1
122	R164H and V240H Replacements by Site-Directed Mutagenesis of TEM-149 Extended-Spectrum Î²-Lactamase: Kinetic Analysis of TEM-149 ^{H240} and TEM-149 ^{H164-H240} Laboratory Mutants. Antimicrobial Agents and Chemotherapy, 2013, 57, 1047-1049.	3.2	1
123	Interaction of carbapenems and Î²-lactamase inhibitors towards CTX-M-15 and CTX-M-15 G238C mutant. Journal of Global Antimicrobial Resistance, 2017, 10, 95-100.	2.2	1
124	Amino Acid Replacement at Position 228 Induces Fluctuation in the â„¦-Loop of KPC-3 and Reduces the Affinity against Oxyimino Cephalosporins: Kinetic and Molecular Dynamics Studies. Catalysts, 2020, 10, 1474.	3.5	1
125	Laboratory Variants GES G170L , GES G170K , and GES G170H Increase Carbapenem Hydrolysis and Confer Resistance to Clavulanic Acid. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	1
126	An in vitro investigation of levofloxacin and ciprofloxacin against clinical isolates of Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 2007, 30, 374-376.	2.5	0